HC Wainwright Issues Positive Forecast for ProQR Therapeutics (NASDAQ:PRQR) Stock Price

ProQR Therapeutics (NASDAQ:PRQR) had its price target raised by HC Wainwright from $10.00 to $12.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on PRQR. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

ProQR Therapeutics Trading Down 2.9 %

Shares of ProQR Therapeutics stock opened at $1.69 on Friday. The company has a market cap of $138.04 million, a price-to-earnings ratio of -5.28 and a beta of 0.24. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62. The company’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $2.62.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $30,000. Invesco Ltd. acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics in the fourth quarter valued at $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $40,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of ProQR Therapeutics during the fourth quarter valued at approximately $54,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).